FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy ...

A growing number of organizations are embracing Large Language Models (LLMs). LLMs excel at interpreting natural language, ...

Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

Learn how to shield your website from external threats using strong security tools, updates, monitoring, and expert ...

Company Successfully Executed Distribution of $500,000 in Cash and $500,000 in BONK Digital Assets Prior to Year-End; ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

OpenAI develops automated attacker system to test ChatGPT Atlas browser security against prompt injection threats and ...

Americans can now purchase the starter dose of blockbuster weight-loss drug Wegovy as a pill, drug maker Novo Nordisk announced Monday. Other strengths will be available as pills by the end of the ...

The Blackrod asset is said to contain significant reserves and contingent resources, with regulatory approval permitting ...

The injection molded automotive parts market is driven by rising vehicle production, lightweight materials, and ...